How much revenue does Jagsonpal Pharmaceuticals make?

Jagsonpal Pharmaceuticals reported 2.87 billion INR in revenue for fiscal year 2026, up 6.9% from 2.69 billion INR in fiscal year 2025.

Where does Jagsonpal Pharmaceuticals make most of its revenue?

India: 99% of revenue by region in fiscal year 2025, followed by Rest of The World (1%).

What companies are similar to Jagsonpal Pharmaceuticals?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Panacea Biotec Limited (PANACEABIO.NS), Indoco Remedies Limited (INDOCO.NS), Sakar Healthcare Limited (SAKAR.NS), Bharat Parenterals Ltd (BPLPHARMA.BO).

Jagsonpal Pharmaceuticals Limited (JAGSNPHARM.NS) Stock

About Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. J...

At a glance

Jagsonpal Pharmaceuticals reported revenue of 2.87 billion INR for fiscal year 2026, up 6.9% from fiscal year 2025, and net income of 430.82 million INR. India was its largest region in fiscal year 2025, with 99% of revenue.

Figures from company filings; latest fiscal year ended March 31, 2026.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.